|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alchemia Ltd, of Brisbane, Australia, said it has gained more than 90 percent of Meditech Ltd., of Melbourne, Australia, and will proceed to compulsory acquisition, with an offer expected to close at the end of this month. The merger plan, disclosed in March, has Alchemia offering one share for every nine Meditech shares, valuing Meditech at $16.9 million. Meditech has a product in Phase II trials in metastatic colorectal cancer patients and two anticancer products that have completed Phase I trials. Separately, Alchemia and Euroscreen SA, of Brussels, Belgium, entered a collaboration for drug discovery in the area of G protein coupled receptors. That deal brings ...